Cytek Biosciences (CTKB) Cash from Operations Growth (1y) (2021 - 2026)
Cytek Biosciences (CTKB) Cash from Operations Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.95 Bn | 176.66 Bn | 6.27 Bn | -7.20% |
| 2 | Stryker | 128.83 Bn | 125.95 Bn | 3.81 Bn | 132.40% |
| 3 | Medtronic | 108.81 Bn | 99.59 Bn | 6.41 Bn | 1.78% |
| 4 | Boston Scientific | 68.39 Bn | 66.94 Bn | 3.61 Bn | -35.67% |
| 5 | Edwards Lifesciences | 48.28 Bn | 44.60 Bn | 1.29 Bn | -84.38% |
| 6 | Dexcom | 28.39 Bn | 27.27 Bn | 750.30 Mn | 185.96% |
| 7 | GE HealthCare Technologies | 28.30 Bn | 26.01 Bn | 1.98 Bn | 16.00% |
| 8 | Smith & Nephew | 26.95 Bn | 26.37 Bn | - | - |
| 9 | Koninklijke Philips | 25.45 Bn | 22.32 Bn | 2.07 Bn | 122.43% |
| 10 | Cytek Biosciences | 564.37 Mn | 498.67 Mn | 21.25 Mn | -2,088.80% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,088.80% |
| Dec 31, 2025 | -138.61% |
| Sep 30, 2025 | -129.48% |
| Jun 30, 2025 | -98.26% |
| Mar 31, 2025 | -103.16% |
| Dec 31, 2024 | -79.01% |
| Sep 30, 2024 | 411.89% |
| Jun 30, 2024 | 317.68% |
| Mar 31, 2024 | 38.45% |
| Dec 31, 2023 | 53.59% |
| Sep 30, 2023 | 43.51% |
| Jun 30, 2023 | 69.81% |
| Mar 31, 2023 | 293.11% |
| Dec 31, 2022 | 13.67% |
| Sep 30, 2022 | -746.34% |
| Jun 30, 2022 | -141.19% |
| Mar 31, 2022 | -176.49% |
| Dec 31, 2021 | -53.20% |
| Sep 30, 2021 | -47.01% |